NEW YORK, NY / ACCESSWIRE / November 24, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has initiated coverage of Propanc Health Group Corp.. (OTCQB: PPCH) with a Price Target of $1.52.
The report is available here: PPCH Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.
“Propanc’s pro-enzyme therapy- chiefly its lead drug candidate, PRP- aims to solve this problem by targeting malignant cancer cells through multiple pathways that creates a lasting clinical benefit for the patient. Propanc is now ready to complete the formal animal studies that precede the human trials planned for 2016. Upon commercialization, the drug will be marketed to oncologists across global territories for specific cancer indications aggregating a $9bn total addressable market.,” stated Ajay Tandon, CEO of SeeThruEquity. “We are initiating coverage with a 12-month price target of $1.52 per share.”
Additional highlights from the update are as follows:
Significantly positive pre-clinical study results
PPCH recently completed animal efficacy studies in mice through our contract research partner, vivoPharm, in Hershey, PA. During the course of these studies, PPCH discovered a new target therapeutic dose range using proenzymes for treating cancer. The company filed a patent application in support of this discovery earlier this month.
Recent capital raise to support upcoming research trials and operations
On November 10, 2015, Propanc announced it secured $4 million from an institutional investor in order to progress their lead product, PRP, towards human trials. The total deal size is sufficient to support upcoming research and development activities in the preparation and commencement of human trials for their lead product, PRP. Also, it is expected to sufficiently cover the Company’s operations over the next 12 months. The global industry for colorectal cancer is projected to reach $8.8 billion by 2020 and the worldwide pancreatic cancer market is expected to surpass $1.2 billion by 2015 representing a significant opportunity for PPCH.
Cell Culture Studies Prompt Patent Application
PPCH recently made some discoveries whilst undertaking cell culture studies on the mechanism of action of proenzymes with its research partenrs in Spain – the Universities of Granada and Jaén and expect to file a patent application on the subject matter soon. The company is also waiting on a final report after some repeat experiments were conducted to help support the application.
Please review important disclosures on SeeThruEquity’s website at www.seethruequity.com.
About Propanc Health Group Corp
Propanc Health Group is a development stage healthcare company that is currently focused on developing new cancer treatments for patients, suffering from pancreatic and colorectal cancer. Propanc has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors recurring and spreading through the body. The Company’s leading products are variations upon novel formulation and involve or employ pro-enzymes, which are inactive precursors of enzymes.
For more information on the Company, its products and services, please visit www.propanc.com.
SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.